Fennec Pharmaceuticals Inc.

Contributing Author

Recent Articles by Fennec Pharmaceuticals Inc.

Dec-09	Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors FENC GlobeNewswire
Dec-02	Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK in Japan to Reduce Cisplatin-Induced Hearing Loss FENC GlobeNewswire
Nov-26	Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference FENC GlobeNewswire
Nov-19	Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption FENC GlobeNewswire
Nov-18	Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada FENC GlobeNewswire
Nov-17	Fennec Pharmaceuticals Announces Closing of Offering of Common Shares FENC GlobeNewswire
Nov-13	Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada FENC GlobeNewswire
Nov-13	Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares FENC GlobeNewswire
Nov-13	Fennec Pharmaceuticals Announces Proposed Offering of Common Shares FENC GlobeNewswire
Nov-13	Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update FENC GlobeNewswire
Aug-14	Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update FENC GlobeNewswire
Aug-11	Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025 FENC GlobeNewswire
Jun-03	Fennec Announces Results of Annual Meeting FENC GlobeNewswire
May-13	Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update FENC GlobeNewswire
May-08	Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 FENC GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.